受强制性开放获取政策约束的文章 - Bryan Schneider了解详情
无法在其他位置公开访问的文章：10 篇
Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial
SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ...
Journal of Clinical Oncology 39 (21), 2375-2385, 2021
强制性开放获取政策： Susan G. Komen
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH)(TBCRC033: ATEMPT Trial)
KJ Ruddy, Y Zheng, N Tayob, J Hu, CT Dang, DA Yardley, SJ Isakoff, ...
Breast Cancer Research and Treatment 189 (1), 103-110, 2021
强制性开放获取政策： Susan G. Komen
Intrinsic subtype‐associated changes in the plasma proteome in breast cancer
H Nakshatri, G Qi, J You, B Kerry, B Schneider, R Zon, C Buck, F Regnier, ...
PROTEOMICS–Clinical Applications 3 (11), 1305-1313, 2009
强制性开放获取政策： US National Institutes of Health
A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors
EG Chiorean, S Malireddy, AE Younger, DR Jones, MJ Waddell, MI Sloop, ...
Cancer chemotherapy and pharmacology 66, 441-448, 2010
强制性开放获取政策： US National Institutes of Health
Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes
BP Schneider, M Radovich, DA Flockhart, JS Carpenter, L Li, JD Robarge, ...
Breast cancer research and treatment 116, 543-549, 2009
强制性开放获取政策： US National Institutes of Health
Resequencing of the vascular endothelial growth factor promoter reveals haplotype structure and functional diversity
M Radovich, BA Hancock, N Kassem, D Mi, TC Skaar, BP Schneider
Angiogenesis 13, 211-218, 2010
强制性开放获取政策： US National Institutes of Health
Racial disparities in breast cancer: from detection to treatment
JC Chen, DG Stover, TJ Ballinger, JG Bazan, BP Schneider, BL Andersen, ...
Current oncology reports 26 (1), 10-20, 2024
强制性开放获取政策： US National Institutes of Health
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
OM Filho, A Giobbie-Hurder, NU Lin, M Faggen, S Come, T Openshaw, ...
Breast cancer research and treatment 185, 135-144, 2021
强制性开放获取政策： Susan G. Komen
Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving doxorubicin and cyclophosphamide.
AM Wessels, DA Flockhart, JS Carpenter, M Radovich, L Li, KD Miller, ...
Breast Journal 17 (5), 2011
强制性开放获取政策： US National Institutes of Health
Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large …
M Lustberg, X Wu, JL Fernández-Martínez, EJ de Andrés-Galiana, ...
Supportive Care in Cancer 31 (2), 139, 2023
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：78 篇
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline
DL Hershman, C Lacchetti, RH Dworkin, EM Lavoie Smith, J Bleeker, ...
Journal of clinical oncology 32 (18), 1941-1967, 2014
强制性开放获取政策： US National Institutes of Health
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update
CL Loprinzi, C Lacchetti, J Bleeker, G Cavaletti, C Chauhan, DL Hertz, ...
Journal of Clinical Oncology 38 (28), 3325-3348, 2020
强制性开放获取政策： US National Institutes of Health
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with …
BP Schneider, M Wang, M Radovich, GW Sledge, S Badve, A Thor, ...
Journal of Clinical Oncology 26 (28), 4672-4678, 2008
强制性开放获取政策： US National Institutes of Health
Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer
SM Tolaney, H Guo, S Pernas, WT Barry, DA Dillon, L Ritterhouse, ...
Journal of Clinical Oncology 37 (22), 1868-1875, 2019
强制性开放获取政策： US National Institutes of Health
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years
AJ Tevaarwerk, RJ Gray, BP Schneider, ML Smith, LI Wagner, JH Fetting, ...
Cancer 119 (6), 1140-1148, 2013
强制性开放获取政策： US National Institutes of Health
Advanced cognitive training for breast cancer survivors: a randomized controlled trial
D Von Ah, JS Carpenter, A Saykin, P Monahan, J Wu, M Yu, G Rebok, ...
Breast cancer research and treatment 135, 799-809, 2012
强制性开放获取政策： US National Institutes of Health
Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199
BP Schneider, L Li, M Radovich, F Shen, KD Miller, DA Flockhart, G Jiang, ...
Clinical Cancer Research 21 (22), 5082-5091, 2015
强制性开放获取政策： US National Institutes of Health, Susan G. Komen
Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial
CE Mosher, E Secinti, R Li, AT Hirsh, J Bricker, KD Miller, B Schneider, ...
Supportive Care in Cancer 26, 1993-2004, 2018
强制性开放获取政策： US National Institutes of Health
Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor–positive …
MN Dickler, WT Barry, CT Cirrincione, MJ Ellis, ME Moynahan, F Innocenti, ...
Journal of Clinical Oncology 34 (22), 2602-2609, 2016
强制性开放获取政策： US National Institutes of Health
Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability
RB Slee, CM Steiner, BS Herbert, GH Vance, RJ Hickey, T Schwarz, ...
Oncogene 31 (27), 3244-3253, 2012
强制性开放获取政策： US National Institutes of Health, German Research Foundation
出版信息和资助信息由计算机程序自动确定